[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Alberta Health services\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":85},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100625940","phase-1-bacteriophage-for-chronic-multidrug-resistant-mycobacterium-abscessus-subsp-abscessus-pulmonary-infection-100625940",false,"NCT07429162","Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection","DP-QB-MYA-002 Phage Cocktail for Chronic Multidrug-Resistant (MDR) Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection","Inclusion Criteria:\n\n* Consent to participation\n\nExclusion Criteria:\n\n* non-consent to participation","ALL","18 Years",{"count":19,"type":20},1,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The objective of this study is to evaluate mycobacteriophage therapy using in-vitro validated mycobacteriophage DP-QB-MYA-002 in combination with conventional antimycobacterial agents for the treatment of multidrug-resistant Mycobacterium abscessus pulmonary disease, with the goal of reducing mycobacterial burden and improving pulmonary outcomes.",[26,27,28],"Mycobacterium Abscessus Infection","Bacteriophage Therapy","Pulmonary Disease","NOT_YET_RECRUITING","2026-02-17",{"date":32,"type":33},"2026-02-24","ACTUAL",{"date":35,"type":20},"2026-07-02",{"date":37,"type":20},"2028-07-02",{"name":39,"class":40},"Alberta Health services","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100553700","prostate-cancer-18f-psma-1007-petct-access-trial-100553700","NCT06489496","Prostate Cancer 18F-PSMA-1007 PET\u002FCT Access Trial","PAX","Inclusion Criteria:\n\n1. Age greater than or equal to 18 years.\n2. Able and willing to follow instructions and comply with the protocol.\n3. Provide written informed consent prior to participation in the study.\n4. One of the following:\n\n   * a history of radical prostatectomy for treatment of prostate cancer, and a serum prostate specific antigen (PSA) ≥ 0.2 µg\u002FL\n   * a history of radiotherapy, cryotherapy, or brachytherapy for treatment of prostate cancer, and a serum PSA progressively rising to ≥ 2 µg\u002FL (minimum two samples) OR a serum PSA doubling-time of \\\u003C 9 months\n   * a history of biopsy-proven prostate cancer and high-risk features for metastatic disease prior to treatment with radical prostatectomy, radiotherapy, cryotherapy, brachytherapy, or other similar therapy. High-risk features include a Gleason score ≥ 8, serum PSA \\> 20 µg\u002FL, OR minimum clinical T-stage T3a\n   * patients who do not meet criteria 1-3 but in whom a 18F-PSMA-1007 PET\u002FCT scan is expected to provide clinical benefit as determined by a Urologist, Radiation Oncologist, Medical Oncologist, or Nuclear Medicine physician (licensed in Alberta)\n\nExclusion Criteria:\n\n1. Unable to obtain consent\n2. Age less than 18 years.\n3. Unable to lie flat for 30 minutes to compete PET\u002FCT imaging.\n4. Lack of intravenous access","MALE",{"count":50,"type":20},1000,"5 Years","OBSERVATIONAL","Primary objective:\n\n• To determine if 18F-PSMA-1007 PET\u002FCT imaging is effective at diagnosing prostate cancers and\u002For metastases compared to conventional imaging \\[including CT, MRI, 99mTc-MDP Bone Scans as available\\].\n\nSecondary Objective:\n\n* To determine safety by evaluating for adverse events\n* To determine which conventional imaging is being performed when 18F-PSMA-1007 PET\u002FCT imaging is available",[55],"Prostate Cancer","2024-07-03",{"date":58,"type":33},"2024-07-08",{"date":60,"type":20},"2024-10-01",{"date":62,"type":20},"2030-10-01",{"name":39,"class":40},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":19},"100490969","68ga-ha-dotatate-petct-in-adults-with-neuroendocrine-tumors-100490969","NCT05673031","68Ga-HA-DOTATATE PET\u002FCT in Adults With Neuroendocrine Tumors","Inclusion Criteria:\n\n1. Male or female. If female of child-bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test will be required.\n2. Age greater than or equal to 18 years.\n3. Able and willing to follow instructions and comply with the protocol.\n4. Provide written informed consent prior to participation in the study.\n5. Clinically suspected (patients presenting with symptom(s) suggestive of carcinoid syndrome or biochemically suggestive of Neuroendocrine Tumor) or Biopsy proven Neuroendocrine Tumor\n\nExclusion Criteria:\n\n1. Nursing or pregnant females.\n2. Age less than 18 years.\n3. Surgery in the area of interest within the preceding 2 months.","100 Years",{"count":72,"type":20},500,"To determine if 68Ga-HA-DOTATATE PET\u002FCT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging \\[including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET\u002FCT, as available\\]",[75],"Neuroendocrine Tumors (NET)","RECRUITING","2023-01-04",{"date":79,"type":33},"2023-01-05",{"date":81,"type":20},"2023-02-01",{"date":83,"type":20},"2027-01-01",{"name":39,"class":40},""]